Published in Biotech Business Week, February 13th, 2006
The purpose of the research underway is to test the ability of BSD's cancer treatment systems to further improve the results from NCI's endorsed method of injecting chemotherapy drugs into the abdomen after surgery to increase the longevity of women suffering from ovarian cancer.
The BSD-2000 cancer treatment system is well designed to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.